Tysabri Touch Form Pdf. Maintain compliance with the touch prescribing program. Tysabri is a prescription medicine used to treat adults with:
Receiving Your TYSABRI® (natalizumab) Infusion
Web tysabri increases your risk of getting a rare brain infection—called progressive multifocal leukoencephalopathy (pml)—that most leads to death instead severe disability. Information prescribers, infusion center healthcare providers, and patients with the risk of progressive multifocal leukoencephalopathy (pml) associated with tysabri including the increased risk of pml with treatment duration and prior immunosuppressant use. This document may not be part of the latest approved prescribing program tysabri outreach: Although you have been receiving tysabri for 2 years, it is important that you are reminded that the risk of pml increases beyond this time. Reduce administrative burden/paperwork for prescribers and infusion sites. Unified commitment to health phone: Tysabri increases the risk of pml Web when your doctor writes you a prescription for tysabri, both of you will review, complete, and sign the enrollment form for the touch prescribing program. Web the touch prescribing program has designed to: Maintain compliance with the touch prescribing program.
This document may not be part of the latest approved prescribing program tysabri outreach: Web tysabri is an integrin receptor antagonist indicated for treatment of: Maintain compliance with the touch prescribing program. This document may not be part of the latest approved prescribing program tysabri outreach: Reduce administrative burden/paperwork for prescribers and infusion sites. Web when your doctor writes you a prescription for tysabri, both of you will review, complete, and sign the enrollment form for the touch prescribing program. This is to make sure that you are informed about the risks of treatment with tysabri, including the risk of progressive multifocal leukoencephalopathy (pml). Verify that the patient is currently authorized to receive tysabri prior to each infusion provide the patient with a copy of the patient medication guide prior to each infusion Although you have been receiving tysabri for 2 years, it is important that you are reminded that the risk of pml increases beyond this time. Web tysabri treatment continuation form tysabri (natalizumab) 300 mg concentrate solution for infusion this form should be read carefully before continuing tysabri treatment for more than 2 years. Unified commitment to health phone:
